IOVA

Iovance Biotherapeutics (IOVA)

About Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Details

Daily high

$2.32

Daily low

$2.08

Price at open

52 Week High

$8.15

52 Week Low

$1.64

Market cap

893.2M

Dividend yield

0.00%

Volume

1,916

Avg. volume

9.6M

P/E ratio

-1.87

Iovance Biotherapeutics News